Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

4.170 -0.080 (-1.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,548
Open 4.250
Bid (Size) 4.140 (1)
Ask (Size) 4.220 (12)
Prev. Close 4.250
Today's Range 4.140 - 4.349
52wk Range 2.190 - 5.800
Shares Outstanding 24,755,873
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
From Abeona Therapeutics Inc.
Via GlobeNewswire
3 Biotech Blockbusters to Turn $5,000 Into $50,000
These transformative early-stage biotech stocks can deliver triple-digit upside if their key milestones are achieved on time. 
Via InvestorPlace

Performance

YTD
+45.80%
+45.80%
1 Month
-0.71%
-0.71%
3 Month
-4.14%
-4.14%
6 Month
+48.40%
+48.40%
1 Year
+22.29%
+22.29%

More News

Read More
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
From Abeona Therapeutics Inc.
Via GlobeNewswire
Recap: Abeona Therapeutics Q1 Earnings
Via Benzinga
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Joins Rare Disease Company Coalition
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Reports First Quarter 2023 Financial Results
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces New Employee Inducement Grants
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
From Abeona Therapeutics Inc.
Via GlobeNewswire
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
From Abeona Therapeutics Inc.
Via GlobeNewswire
Three Small-Cap Biotech Stocks to Consider Now
Via MarketBeat
PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.